Analysts Conflicted on These Healthcare Names: CareDx (CDNA) and Pfizer (PFE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on CareDx (CDNA) and Pfizer (PFE).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CareDx (CDNA)
In a report released today, Andrew Brackmann from William Blair maintained a Hold rating on CareDx. The company’s shares closed last Thursday at $20.75.
According to TipRanks.com, Brackmann is a 4-star analyst with an average return of
Currently, the analyst consensus on CareDx is a Moderate Buy with an average price target of $25.00, which is a 42.3% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
Pfizer (PFE)
In a report released today, Asad Haider from Goldman Sachs maintained a Buy rating on Pfizer, with a price target of $33.00. The company’s shares closed last Thursday at $27.40.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $29.47, implying an 8.4% upside from current levels. In a report issued on April 14, Scotiabank also maintained a Buy rating on the stock with a $30.00 price target.
Read More on CDNA:
Disclaimer & DisclosureReport an Issue
- CareDx Divests Lab Products to Refocus on Core Growth
- Closing Bell Movers: JB Hunt up 2% after Q1 earnings beat
- CareDx up 20% at $21 after Q1 pre-announcement, Lab Products divestment
- CareDx to divest Lab Products unit to EuroBio for $170M cash consideration
- CareDx reports preliminary Q1 revenue roughly $118M, consensus $102.49M
